FDA approves betrixaban for VTE prophylaxis

 

Betrixaban, a factor Xa inhibitor, has been approved for the prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized with an acute illness, according to an announcement from the Food and Drug Administration.

Approval was based on results from a randomized, double-blind clinical trial in which over 7,000 hospitalized patients at risk for VTE received either extended-duration betrixaban (35-42 days) or short duration enoxaparin (6-14 days), a low molecular weight heparin administered subcutaneously. The rate of deep vein thrombosis, nonfatal pulmonary embolism, or VTE-related death was 4.4% among patients receiving betrixaban and 6% among patients receiving enoxaparin (relative risk, 0.75; 95% confidence interval: 0.61, 0.91).

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

A total of 54% of patients receiving betrixaban had at least one adverse event, compared with 52% of patients receiving enoxaparin. The incidence of serious adverse events was also similar for both groups at 18% among betrixaban-treated patients and 17% among enoxaparin-treated patients. The most common adverse events were related to bleeding (2.4% for betrixaban and 1.2% for enoxaparin), which was also the most common reason for treatment discontinuation in both groups.

The recommended dosage for betrixaban is 80 mg per day for 35-42 days at the same time every day with food, after a dose of 160 mg on the first day of treatment.

Betrixaban will be marketed as Bevyxxa by Portola.

Find the full FDA announcement and prescribing information on the FDA website.

[email protected]

 

Betrixaban, a factor Xa inhibitor, has been approved for the prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized with an acute illness, according to an announcement from the Food and Drug Administration.

Approval was based on results from a randomized, double-blind clinical trial in which over 7,000 hospitalized patients at risk for VTE received either extended-duration betrixaban (35-42 days) or short duration enoxaparin (6-14 days), a low molecular weight heparin administered subcutaneously. The rate of deep vein thrombosis, nonfatal pulmonary embolism, or VTE-related death was 4.4% among patients receiving betrixaban and 6% among patients receiving enoxaparin (relative risk, 0.75; 95% confidence interval: 0.61, 0.91).

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

A total of 54% of patients receiving betrixaban had at least one adverse event, compared with 52% of patients receiving enoxaparin. The incidence of serious adverse events was also similar for both groups at 18% among betrixaban-treated patients and 17% among enoxaparin-treated patients. The most common adverse events were related to bleeding (2.4% for betrixaban and 1.2% for enoxaparin), which was also the most common reason for treatment discontinuation in both groups.

The recommended dosage for betrixaban is 80 mg per day for 35-42 days at the same time every day with food, after a dose of 160 mg on the first day of treatment.

Betrixaban will be marketed as Bevyxxa by Portola.

Find the full FDA announcement and prescribing information on the FDA website.

[email protected]

 

Betrixaban, a factor Xa inhibitor, has been approved for the prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized with an acute illness, according to an announcement from the Food and Drug Administration.

Approval was based on results from a randomized, double-blind clinical trial in which over 7,000 hospitalized patients at risk for VTE received either extended-duration betrixaban (35-42 days) or short duration enoxaparin (6-14 days), a low molecular weight heparin administered subcutaneously. The rate of deep vein thrombosis, nonfatal pulmonary embolism, or VTE-related death was 4.4% among patients receiving betrixaban and 6% among patients receiving enoxaparin (relative risk, 0.75; 95% confidence interval: 0.61, 0.91).

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

A total of 54% of patients receiving betrixaban had at least one adverse event, compared with 52% of patients receiving enoxaparin. The incidence of serious adverse events was also similar for both groups at 18% among betrixaban-treated patients and 17% among enoxaparin-treated patients. The most common adverse events were related to bleeding (2.4% for betrixaban and 1.2% for enoxaparin), which was also the most common reason for treatment discontinuation in both groups.

The recommended dosage for betrixaban is 80 mg per day for 35-42 days at the same time every day with food, after a dose of 160 mg on the first day of treatment.

Betrixaban will be marketed as Bevyxxa by Portola.

Find the full FDA announcement and prescribing information on the FDA website.

[email protected]